MariMed Inc. (MRMD) stock
MRMDOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$0.06−0.00 (-3.39%)
Close on Oct 19, 2026Market cap $22.97MP/E –Yield –
MariMed operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MariMed's operating income for the twelve months ending Sep 30, 2026 was -$2.76M, down 1265.0% year over year. For fiscal 2025 it was -$2.82M, down 208.1% from the year before. The highest annual figure on record is $26.86M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.82M | -208.1% |
| FY2024 | Dec 31, 2024 | $2.61M | -81.9% |
| FY2023 | Dec 31, 2023 | $14.39M | -29.4% |
| FY2022 | Dec 31, 2022 | $20.37M | -24.2% |
| FY2021 | Dec 31, 2021 | $26.86M | +84.9% |
| FY2020 | Dec 31, 2020 | $14.53M | – |
| FY2019 | Dec 31, 2019 | -$41.53M | – |
| FY2018 | Dec 31, 2018 | -$5.36M | -4295.9% |
| FY2017 | Dec 31, 2017 | $127.65K | -83.5% |
| FY2016 | Dec 31, 2016 | $775.30K | – |
| FY2015 | Dec 31, 2015 | -$1.69M | – |
| FY2014 | Dec 31, 2014 | -$817.35K | – |
| FY2013 | Dec 31, 2013 | -$558.15K | – |
| FY2012 | Dec 31, 2012 | -$774.79K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.22M | -23.6% |
| Q2 FY2026 | Jun 30, 2026 | $418.00K | -58.9% |
| Q1 FY2026 | Mar 31, 2026 | $125.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.53M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.60M | +18.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.02M | +6.3% |
| Q1 FY2025 | Mar 31, 2025 | -$910.00K | -145.0% |
| Q4 FY2024 | Dec 31, 2024 | -$1.47M | -160.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.35M | -59.1% |
| Q2 FY2024 | Jun 30, 2024 | $956.00K | -73.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.02M | -60.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.41M | -21.9% |
| Q3 FY2023 | Sep 30, 2023 | $3.29M | -42.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.55M | -21.1% |
| Q1 FY2023 | Mar 31, 2023 | $5.14M | -27.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.09M | +156.8% |
| Q3 FY2022 | Sep 30, 2022 | $5.74M | -18.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.50M | -44.1% |
| Q1 FY2022 | Mar 31, 2022 | $7.05M | +107.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.20M | -42.7% |
| Q1 FY2021 | Mar 31, 2021 | $7.04M | +598.7% |
| Q4 FY2020 | Dec 31, 2020 | $8.04M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.40M | +249.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.10M | -60.8% |
| Q1 FY2020 | Mar 31, 2020 | $1.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$47.64M | – |
| Q3 FY2019 | Sep 30, 2019 | $972.63K | – |
| Q2 FY2019 | Jun 30, 2019 | $5.35M | +1112.9% |
| Q1 FY2019 | Mar 31, 2019 | -$222.28K | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.94M | – |
| Q3 FY2018 | Sep 30, 2018 | -$548.99K | -291.3% |
| Q2 FY2018 | Jun 30, 2018 | $441.04K | -26.6% |
| Q1 FY2018 | Mar 31, 2018 | -$321.64K | -240.7% |
| Q4 FY2017 | Dec 31, 2017 | -$989.06K | -262.0% |
| Q3 FY2017 | Sep 30, 2017 | $287.04K | +421.5% |
| Q2 FY2017 | Jun 30, 2017 | $601.12K | – |
| Q1 FY2017 | Mar 31, 2017 | $228.55K | – |
| Q4 FY2016 | Dec 31, 2016 | $610.52K | – |
| Q3 FY2016 | Sep 30, 2016 | $55.04K | – |
See a number that looks wrong?